Skip to main content

Table 1 Baseline patient characteristics

From: A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

 

Mean (SD)

Median (range)

Age (years)

74 (5.1)

74 (65–80)

KPS

87.7 (9.7)

90 (70–100)

Hemoglobin (g/dl)

12.1 (1.3)

12.1 (10.0–14.3)

PSA (ng/ml)

665 (1230)

218.3 (9–5754)

Alkaline phosphatase (U/l)

223 (208)

126.5 (51–768)

Duration of androgen deprivation (months)

65.8 (36.3)

60 (8–132)

Secondary hormonal manipulations

2.4 (1.5)

2 (0–5)

Primary Therapy

Number

 

   Prostatectomy

13

 

   Prostatectomy and radiation

7

 

   Radiation alone

2

 

   Androgen-deprivation therapy alone

7

 

Sites of Disease

  

   Bone only

14

 

   Visceral only

2

 

   Both

6